William Blair Has Positive Outlook for SPRY FY2024 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Equities research analysts at William Blair lifted their FY2024 EPS estimates for shares of ARS Pharmaceuticals in a report issued on Wednesday, November 13th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings per share of ($0.17) for the year, up from their prior forecast of ($0.63). William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.56) per share. William Blair also issued estimates for ARS Pharmaceuticals’ Q4 2024 earnings at $0.26 EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.47) EPS and FY2026 earnings at $0.94 EPS.

Other analysts have also recently issued reports about the stock. Leerink Partners lifted their target price on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research note on Friday, September 20th. Raymond James raised shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $18.00 to $22.00 in a research note on Tuesday, August 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $24.00.

ARS Pharmaceuticals Stock Performance

SPRY stock opened at $13.78 on Monday. The stock has a market capitalization of $1.34 billion, a P/E ratio of -27.02 and a beta of 0.90. ARS Pharmaceuticals has a one year low of $4.64 and a one year high of $18.51. The company has a 50 day moving average price of $14.67 and a two-hundred day moving average price of $11.78.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Peter A. Thompson sold 407,700 shares of ARS Pharmaceuticals stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $13.56, for a total value of $5,528,412.00. Following the transaction, the director now owns 544,677 shares in the company, valued at $7,385,820.12. This trade represents a 42.81 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder James E. Flynn sold 528,456 shares of ARS Pharmaceuticals stock in a transaction on Monday, November 11th. The shares were sold at an average price of $18.04, for a total transaction of $9,533,346.24. Following the completion of the transaction, the insider now owns 5,274,735 shares in the company, valued at approximately $95,156,219.40. This trade represents a 9.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,411,851 shares of company stock worth $21,559,378 in the last quarter. 40.10% of the stock is owned by insiders.

Hedge Funds Weigh In On ARS Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. lifted its holdings in shares of ARS Pharmaceuticals by 14.8% during the 1st quarter. RA Capital Management L.P. now owns 10,860,977 shares of the company’s stock valued at $110,999,000 after acquiring an additional 1,401,299 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of ARS Pharmaceuticals by 37.0% during the 1st quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock valued at $29,500,000 after acquiring an additional 779,969 shares in the last quarter. State Street Corp lifted its holdings in shares of ARS Pharmaceuticals by 10.4% during the 3rd quarter. State Street Corp now owns 2,049,542 shares of the company’s stock valued at $29,718,000 after acquiring an additional 193,321 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of ARS Pharmaceuticals by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,234,805 shares of the company’s stock valued at $17,909,000 after acquiring an additional 38,927 shares in the last quarter. Finally, Royce & Associates LP lifted its holdings in shares of ARS Pharmaceuticals by 7.1% during the 3rd quarter. Royce & Associates LP now owns 691,455 shares of the company’s stock valued at $10,026,000 after acquiring an additional 45,755 shares in the last quarter. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.